Hims & Hers Q1 2026 Earnings: Big Subscriber Jump But Misses Estimates – Raises Full-Year Outlook
Hims & Hers missed earnings, lost money, but grew users and expects stronger future growth with higher revenue guidance.
/ 1656 items
#XY↓
Alpha Tau Reports Breakthrough Interim Results in Brain Cancer Trial: 100% Disease Control and 67% Complete Response
Alpha Tau’s brain cancer trial shows 2/3 glioblastoma patients’ tumors disappeared, all controlled, with good safety so far.
MBX Biosciences Just Took a Big Step Toward Monthly Obesity Injections
MBX drug showed early weight loss up to 7% in 8 weeks, was well tolerated, and may become once-monthly treatment.
Zai Lab’s Zoci Wins U.S. FDA Fast Track Designation for Aggressive Rare Cancer (epNECs)
Zai Lab’s drug Zoci got FDA Fast Track for rare cancer epNEC, showing 38% tumor response in early trials, speeding approval path.
INBRX-106 + Keytruda Nearly Doubles Response Rate in First-Line Head & Neck Cancer
Inhibrx drug INBRX-106 with pembrolizumab boosted tumor response in head/neck cancer, showing higher shrinkage and immune activation.
Coherus Stock Soars on Wall Street Radar: 585% Upside Potential
Guggenheim rates Coherus Oncology Buy with $12 target vs $1.75 now, seeing big upside in cancer drug pipeline but high risk.